# FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Source: https://onco.cc/trials/nct07446322/  
OnCo record `nct07446322` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Bevacizumab, FOLFIRI in colorectal cancer, run by Oncolytics Biotech, now recruiting.

## Summary

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer is a phase 2 interventional study registered as NCT07446322 by Oncolytics Biotech, with 60 participants planned, started 2026-04-30 and due to reach its primary completion in 2027-08-30. Interventions recorded: Bevacizumab, FOLFIRI, Pelareorep. Conditions listed: Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07446322
- Phase: 2
- Setting: An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer
- Sponsor: Oncolytics Biotech
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07446322: https://clinicaltrials.gov/study/NCT07446322

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/)
- companies: [Oncolytics Biotech](https://onco.cc/companies/oncolytics-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07446322.json